Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.

@article{Gke2013SaxagliptinVG,
  title={Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.},
  author={Burkhard J. G{\"o}ke and Baptist Gallwitz and Johan G Eriksson and {\AA}sa Hellqvist and Ingrid A M Gause-Nilsson},
  journal={International journal of clinical practice},
  year={2013},
  volume={67 4},
  pages={307-16}
}
AIM To compare the long-term safety, tolerability and efficacy of saxagliptin vs. glipizide as add-on therapy to metformin. METHODS Adults with glycated haemoglobin (HbA1c) > 6.5-10% (on stable metformin ≥ 1500 mg/day) were randomised to saxagliptin 5 mg/day (n = 428) or glipizide titrated from 5 to 20 mg/day (mean dose 15 mg/day; n = 430) for 52 weeks… CONTINUE READING